N-methyl-D-aspartate receptor glycine modulatory site (NR2B-containing) (NMDAR glycine site (NR2B))

The N-methyl-D-aspartate (NMDA) receptor is a heterotetrameric ligand-gated ion channel that mediates the slow component of excitatory synaptic transmission and is vital for synaptic plasticity, learning, and memory [1, 3]. Functional NMDA receptors typically consist of two glycine-binding GluN1 subunits and two glutamate-binding GluN2 subunits (NR2A-D). The glycine modulatory site, also known as the glycine-B site, is located on the GluN1 subunit and must be occupied by a co-agonist (glycine or D-serine) for the channel to open upon glutamate binding [3]. While the physical binding site is on GluN1, the pharmacological sensitivity and functional outcomes of glycine site ligands are significantly influenced by the specific GluN2 subtype present, with NR2B-containing receptors being of particular interest due to their enrichment in the forebrain and involvement in mood regulation and cognitive processing [1, 4]. Targeting the glycine site of NR2B-containing receptors has emerged as a therapeutic strategy for treating major depressive disorder and cognitive deficits, as seen with partial agonists like rapastinel, which aim to enhance NMDA receptor function without the severe dissociative side effects associated with non-selective pore blockers like ketamine [2, 5]. Conversely, glycine site antagonists have been explored for neuroprotection in stroke and chronic pain, though clinical success has been limited by safety and efficacy challenges [3].

Other names

Glycine-B siteStrychnine-insensitive glycine siteGluN1/GluN2B glycine binding siteNMDA receptor glycine co-agonist site

Ligands bind to the strychnine-insensitive glycine site on the GluN1 subunit. In the presence of NR2B subunits, these ligands modulate the receptor's gating properties, calcium permeability, and synaptic plasticity, often acting as partial agonists to enhance signaling without inducing excitotoxicity or dissociative effects [1, 2, 3].